Figure 3.
Kaplan-Meier plots comparing ZUMA-5 to SCHOLAR-5 for PFS, OS, and Time-to-next-treatments. Kaplan-Meier curves showing (A) PFS, (B) OS, and (C) time to next treatment in ZUMA-5 (blue) compared with SCHOLAR-5 (red). Shaded area represents 95% CI. Number at risk for the SCHOLAR-5 analysis of PFS was reduced due to the exclusion of DELTA participants from this analysis as PFS was not available in this subgroup. See supplemental Figure 2 for results of all time-to-event outcomes with DELTA participants excluded prior to SMR weight.